Changes in urine proteome accompanying diabetic nephropathy progression

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 1-2, 2015, Pages 27-38

  Lewandowicz, Andrzej ^a   Bakun, Magdalena ^b   Kohutnicki, Rafa ^a   Fabijañska, Agnieszka ^b   Kistowski, Micha ^b   Imiela, Jacek ^a   Dadlez, Micha ^b,c  

^a Laboratory of Nuclear Medicine   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

Author keywords

Amylase; Diabetic kidney disease; Diabetic nephropathy; Exocrine pancreatic insufficiency; Urinary proteome

Indexed keywords

ACETYLGLUCOSAMINIDASE; ALPHA 1 ANTITRYPSIN; ALPHA AMYLASE PANCREAS ISOENZYME; ALPHA1 GLYCOPROTEIN; APOLIPOPROTEIN A1; BETA 2 MICROGLUBULIN; CATHEPSIN D; COLLAGEN ALPHA 1; CYSTATIN C; DEOXYRIBONUCLEASE I; EPIDERMAL GROWTH FACTOR; FATTY ACID BINDING PROTEIN; FETUIN A; GLYCOPROTEIN; HEMOPEXIN; IMMUNOGLOBULIN 3 LAMBDA CHAIN; IMMUNOGLOBULIN GAMMA FC REGION RECEPTOR III A; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LAMBDA LIKE POLYPEPTIDE 5; IMMUNOGLOBULIN RECEPTOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; OSTEOPONTIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROSTAGLANDIN D SYNTHASE; PROTEOME; SERUM ALBUMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC ALPHA 2 GLYCOPROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; HUMAN; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS EXOCRINE INSUFFICIENCY; PROTEIN URINE LEVEL; PROTEOMICS; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; COMPARATIVE STUDY; COMPLICATION; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; URINE;

ADULT; AGED; ALBUMINURIA; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84924285467     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2640     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention (CDC). National chronic kidney disease fact sheet: general information and national estimates on chronic kidney disease in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services (HHS).
2. Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J. 2014; 38: 252-260.
3. United States Renal Data System, 2014 annual data report: An overview of the epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014; Volume 2-ESDR, Table B7.
4. Wołyniec W, Jankowska MM, Król E, et al. Current diagnostic evaluation of autosomal dominant polycystic kidney disease. Pol Arch Med Wewn. 2008; 118: 767-773. Review.
5. Whaley-Connell A, Bomback AS, McFarlane SI, et al.; on behalf of the Kidney Early Evaluation Program Investigators. Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. Cardiorenal Med. 2011; 1: 45-52.
6. Gosmanov AR, Wall BM, Gosmanova EO. Diagnosis and treatment of diabetic kidney disease. Am J Med Sci. 2014; 347: 406-413.
7. Solini A, Penno G, Bonora E, et al. Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Diverging association of reduced GFR and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care. 2012; 35: 143-149.
8. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-232.
9. Trevisan R, Viberti G. Genetic factors in the development of diabetic ne-phropathy. J Lab Clin Med. 1995; 126: 342-349.
10. National Kidney Foundation. http://www2.kidney.org/professionals/KDOQI/guideline-diabetes/guide1.htm. Accessed August 2014.
11. Kanauchi M, Kawano T, Uyama H, et al. Discordance between retinopathy and ne-phropathy in type 2 diabetes. Nephron. 1998; 80: 171-174.
12. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin N Am. 2004; 88: 1001-1036.
13. Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res. 2009; 8: 268-281.
14. Bramham K, Mistry HD, Poston L, et al. The non-invasive biopsy-will urinary proteomics make the renal tissue biopsy redundant? QJM. 2009; 102: 523-538.
15. Kalantari S, Nafar M, Rutishauser D, et al. Predictive urinary biomarkers for steroid-resistant and steroid-sensitive focal segmental glomerulosclero-sis using high resolution mass spectrometry and multivariate statistical analysis. BMC Nephrol. 2014; 15: 141.
16. Arden GB, Sivaprasad S. The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol. 2012; 124: 15-26.
17. Rao PV, Lu X, Standley M, et al. Proteomic identification of urinary bio-markers of diabetic nephropathy. Diabetes Care. 2007; 30: 629-637.
18. Good DM, Zürbig P, Argilés A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010; 9: 2424-2437.
19. Hirawa N, Uehara Y, Ikeda T, et al. Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. Nephron. 2001; 87: 321-327.
20. Bellei E, Rossi E, Lucchi L, et al. Proteomic analysis of early urinary bio-markers of renal changes in type 2 diabetic patients. Proteomics Clin Appl. 2008; 2: 478-491.
21. Kotajima N, Kimura T, Kanda T, et al. Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus. J Diabetes Complications. 2000; 14: 13-17.
22. Siwy J, Schanstra J P, Argiles A, et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant. 2014; 29: 1563-1570.
23. Araki S, Haneda M, Koya D, et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care. 2010; 33: 1805-1810.
24. van der Pijl JW, Daha MR, van den Born J, et al. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane. Diabetologia. 1998; 41: 791-798.
25. Tojo A, Kinugasa S. Mechanisms of glomerular albumin filtration and tubular reabsorption. Int J Nephrol. 2012; 2012: 481520.
26. Roos A, Rastaldi M P, Calvaresi N, et al. Glomerular activation of the lec-tin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17: 1724-1734.
27. Mucha K, Bakun M, Jazwiec R, et al. Complement components, proteolysis-related, and cell communication-related proteins detected in urine proteomics are associated with IgA nephropathy. Pol Arch Med Wewn. 2014; 124: 380-386.
28. Groenestege W, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin. Invest. 2007; 117: 2260-2267.
29. Koyama I, Komine S, Iino N, et al. alpha-Amylase expressed in human liver is encoded by the AMY-2B gene identified in tumorous tissues. Clin Chim Acta. 2001; 309: 73-83.
30. Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011; 8: 405-415.
31. Hardt PD, Ewald N. Exocrine pancreatic insufficiency in diabetes mel-litus: a complication of diabetic neuropathy or a different type of diabetes? Exp Diabetes Res. 2011; 2011: 761950.
32. Blumenthal HT, Probstein JG, Berns AW. Interrelationship of diabetes mellitus and pancreatitis. Arch Surg. 1963; 87: 844-850.
33. Olsen RS. The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material. Acta Pathol Microbiol Scand A. 1978; 86: 361-364.
34. Bilgin M, Balci NC, Momtahen AJ, et al. MRI and MRCP findings of the pancreas in patients with diabetes mellitus: compared analysis with pancreatic exocrine function determined by fecal elastase 1. J Clin Gastroenterol. 2009; 43: 165-170.
35. Shen HN, Chang YH, Chen H F, et al. Increased risk of severe acute pancreatitis in patients with diabetes. Diabet Med. 2012; 29: 1419-1424.
36. Sikkens EC, Cahen DL, van Eijck C, et al. Patients with exocrine insufficiency due to chronic pancreatitis are undertreated: a Dutch national survey. Pancreatology. 2012; 12: 71-73.
37. Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol. 2013; 19: 7276-7281.
38. Duane WC, Frerichs R, Levitt MD. Simultaneous study of the metabolic turnover and renal excretion of salivary amylase-125I and pancreatic amy-lase-131I in the baboon. J Clin Invest. 1972; 51: 1504-1513.
39. Keogh JB, McGeeney K F, Drury MI, et al. Renal clearance of pancreatic and salivary amylase relative to creatinine in patients with chronic renal insufficiency. Gut. 1978; 19: 1125-1130.
40. Maeda M, Otsuki M, Okano K, et al. Clinical evaluation of amylase-cre-atinine clearance ratio and amylase isoenzyme clearance in chronic renal failure. Gastroenterol Jpn. 1981; 16: 242-248.
41. Collen MJ, Ansher A F, Chapman AB, et al. Serum amylase in patients with renal insufficiency and renal failure. Am J Gastroenterol. 1990; 85: 1377-1380.
42. Johnson SG, Ellis CJ, Levitt MD. Mechanism of increased renal clearance of amylase/creatinine in acute pancreatitis. N Engl J Med. 1976; 295: 1214-1217.
43. Hegarty JE, O'Donnell MD, McGeeney K F, et al. Pancreatic and salivary amylase/creatinine clearance ratios in normal subjects and in patients with chronic pancreatitis. Gut. 1978; 19: 350-354.
44. Bakun M, Niemczyk M, Domanski D, et al. Urine proteome of autoso-mal dominant polycystic kidney disease patients. Clin Proteomics. 2012; 9: 13.
45. Chatha RK, Johnson AM, Rothberg PG, et al. Von Hippel-Lindau disease masquerading as autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2001; 37: 852-858.